Resistant hypertension (RH) is defined as blood pressure that remains above target in spite of the concurrent use of three or more classes of antihypertensive drugs at optimized doses (UCRH), with one of them being a diuretic. Moreover, patients whose blood pressure is controlled while using four or more antihypertensive medications are also considered controlled resistant hypertensive (CRH) subjects. Although this definition may be useful in terms of categorizing a larger group of resistant hypertensive individuals, as these two subgroups share high cardiovascular risk, some important clinical and pathophysiologic particularities need to be better evaluated, before considering resistant controlled and uncontrolled patients as part of the same group. We compared cardiovascular characteristics of these two subgroups with resistant hypertension. In spite of some similar features, the UCRH subgroup has cardiovascular phenotypes with worse prognosis, such as increased vascular stiffness and left ventricular hypertrophy, as well as more impaired endothelial function and lower nocturnal blood pressure dipping, among others. Considering these differences, the UCRH subgroup is associated with greater cardiovascular risk and may be considered as more resistant to antihypertensive treatment. In addition to the importance of better prevention and treatment of resistant hypertension by identifying early risk factors and optimizing drug therapy, some clinical implications must be considered when managing controlled and uncontrolled patients as similar to the resistant hypertension group.1006579582Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research (2008) Circulation., 117 (25), pp. e510-e526Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research (2008) Hypertension., 51 (6), pp. 1403-1419Lloyd-Jones, D.M., Evans, J.C., Larson, M.G., O'Donnell, C.J., Roccella, E.J., Levy, D., Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community (2000) Hypertension., 36 (4), pp. 594-599Cushman, W.C., Ford, C.E., Cutler, J.A., Margolis, K.L., Davis, B.R., Grimm, R.H., Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) (2002) J Clin Hypertens (Greenwich)., 4 (6), pp. 393-404Pimenta, E., Gaddam, K.K., Oparil, S., Aban, I., Husain, S., Dell'Italia, L.J., Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial (2009) Hypertension., 54 (3), pp. 475-481Cuspidi, C., Macca, G., Sampieri, L., Michev, I., Salerno, M., Fusi, V., High prevalence of cardiac and extracardiac target organ damage in refractory hypertension (2001) J Hypertens., 19 (11), pp. 2063-2070Salles, G.F., Cardoso, C.R., Pereira, V.S., Fiszman, R., Muxfeldt, E.S., Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: A cohort study (2011) J Hypertens., 29 (10), pp. 2014-2023Salles, G.F., Fiszman, R., Cardoso, C.R., Muxfeldt, E.S., Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension (2007) Hypertension., 50 (4), pp. 723-728Salles, G.F., Cardoso, C.R., Fiszman, R., Muxfeldt, E.S., Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension (2010) Am Heart J., 159 (5), pp. 833-840Gus, M., Silva, D.N., Fernandes, J., Cunha, C.P., Sant'Anna, G.D., Epworth's sleepiness scale in outpatients with different values of arterial blood pressure (2002) Arq Bras Cardiol., 78 (1), pp. 17-24Gus, M., Goncalves, S.C., Martinez, D., de Abreu Silva, E.O., Moreira, L.B., Fuchs, S.C., Risk for Obstructive Sleep Apnea by Berlin Questionnaire, but not daytime sleepiness, is associated with resistant hypertension: A case-control study (2008) Am J Hypertens., 21 (7), pp. 832-835Pedrosa, R.P., Krieger, E.M., Lorenzi-Filho, G., Drager, L.F., Recent advances of the impact of obstructive sleep apnea on systemic hypertension (2011) Arq Bras Cardiol., 97 (2), pp. e40-e47Pedrosa, R.P., Drager, L.F., Gonzaga, C.C., Sousa, M.G., de Paula, L.K., Amaro, A.C., Obstructive sleep apnea: The most common secondary cause of hypertension associated with resistant hypertension (2011) Hypertension., 58 (5), pp. 811-817Whaley-Connell, A., Johnson, M.S., Sowers, J.R., Aldosterone: Role in the cardiometabolic syndrome and resistant hypertension (2010) Prog Cardiovasc Dis., 52 (5), pp. 401-409Sowers, J.R., Whaley-Connell, A., Epstein, M., Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension (2009) Ann Intern Med., 150 (11), pp. 776-783Drager, L.F., Queiroz, E.L., Lopes, H.F., Genta, P.R., Krieger, E.M., Lorenzi-Filho, G., Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecutive patients with the metabolic syndrome (2009) J Cardiometab Syndr., 4 (2), pp. 89-95Martins, L.C., Conceicao, F.L., Muxfeldt, E.S., Salles, G.F., Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension (2012) J Hypertens., 30 (5), pp. 967-973Boer-Martins, L., Figueiredo, V.N., Demacq, C., Martins, L.C., Consolin-Colombo, F., Figueiredo, M.J., Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients (2011) Cardiovasc Diabetol., 10, p. 24Ubaid-Girioli, S., Souza, A.L., Yugar-Toledo, J.C., Martins, L.C., Ferreira-Melo, S., Coelho, O.R., Aldosterone excess or escape: Treating resistant hypertension (2009) J Clin Hypertens (Greenwich)., 11 (5), pp. 245-252Boer-Martins, L., Figueiredo, V.N., Demacq, C., Martins, L.C., Faria, A.P., Moraes, C.D., Leptin and aldosterone in sympathetic activity in resistant hypertension with or without type 2 diabetes (2012) Arq Bras Cardiol., 99 (1), pp. 642-648de Souza, F., Muxfeldt, E., Fiszman, R., Salles, G., Efficacy of spironolactone therapy in patients with true resistant hypertension (2010) Hypertension., 55 (1), pp. 147-152Acelajado, M.C., Pisoni, R., Dudenbostel, T., Dell'Italia, L.J., Cartmill, F., Zhang, B., Refractory hypertension: Definition, prevalence, and patient characteristics (2012) J Clin Hypertens (Greenwich)., 14 (1), pp. 7-12Moreno Jr., H., Coca, A., Resistant and refractory hypertension: Reflections on pathophysiology and terminology (2012) Blood pressure., 21 (4), pp. 209-210Martins, L.C., Figueiredo, V.N., Quinaglia, T., Boer-Martins, L., Yugar-Toledo, J.C., Martin, J.F., Characteristics of resistant hypertension: Ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness (2011) J Hum Hypertens., 25 (9), pp. 532-538Figueiredo, V.N., Yugar-Toledo, J.C., Martins, L.C., Martins, L.B., de Faria, A.P., de Haro Moraes, C., Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure (2012) Blood Press, 21 (1), pp. 31-38Quinaglia, T., Martins, L.C., Figueiredo, V.N., Santos, R.C., Yugar-Toledo, J.C., Martin, J.F., Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension (2011) J Hum Hypertens., 25 (11), pp. 656-664de Haro Moraes, C., Figueiredo, V.N., de Faria, A.P., Barbaro, N.R., Sabbatini, A.R., Quinaglia, T., High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension (2012) J Hum Hypertens, , Jul 19[epub ahead of print]